WO1997021833A1 - Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques - Google Patents

Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques Download PDF

Info

Publication number
WO1997021833A1
WO1997021833A1 PCT/EP1996/005734 EP9605734W WO9721833A1 WO 1997021833 A1 WO1997021833 A1 WO 1997021833A1 EP 9605734 W EP9605734 W EP 9605734W WO 9721833 A1 WO9721833 A1 WO 9721833A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
allele
subject
treatment
dna
Prior art date
Application number
PCT/EP1996/005734
Other languages
English (en)
Inventor
Maureen Claire Royston
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to AU13762/97A priority Critical patent/AU1376297A/en
Publication of WO1997021833A1 publication Critical patent/WO1997021833A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • the present invention relates to methods of assessing the responsiveness of individuals to neuroleptic agents such as clozapine.
  • Schizophrenia is a devastating psychiatric disease for which there is currently no cure, although advances are now being made in understanding its causes and controlling its symptoms. In general the age of onset is in late adolescence and it is a lifelong illness with a poor prognosis. Subjects suffering from schizophrenia may exhibit positive symptoms, for example delusions and hallucinations, and /or negative symptoms such as withdrawal. isolation and demotivation leading ultimately to social decline and withdrawl. There are 600,000 schizophrenics at any one time in the UK and their care has been reported to cost approximately 1.6% of the total healthcare budget.
  • Atypical neuroieptics provide advantages in that they improve both the positive and negative symptoms of schizophrenia and cause virtually no eps.
  • An example of this type of drug is clozapine.
  • clozapine and other atypical neuroleptic agents to treat schizophrenia is reserved for those mdividuals who have failed to respond to treatment with other neuroleptic agents, such as haioperidol.
  • the method may be used more generally to predict whether a patient is likely to respond to any of the existing typical or atypical neuroleptic agents.
  • the present invention therefore provides an objective method of assessing in a subject the likelihood whether said subject will be non-responsive or responsive to treatment with neuroieptics such as clozapine, the method comprising detecting the presence or absence of DNA comprising the E2 allele of the ApoE gene . or the protein expressed by said DNA, in said subject.
  • responders and “non-responders” as used herein are terms well known in the art.
  • GAS Global Assessment Scale
  • BPRS Brief Psychiatric Rating Scale
  • the present invention provides a method for use in assessing whether a subject suffering from a condition which may be treated with a neuroleptic agent will be responsive to treatment with said neuroleptic agent, said method comprising the steps of:
  • the predetermined correlation utilised in step (ii) may itself be obtained by the following series of steps: selecting a population or cohort of subjects diagnosed as suffering from a specified condition suitable for treatment with a neuroleptic agent; treating said cohort with a specified neuroleptic agent; monitoring the outcome of said treatment and identifying responders and non-responders to the said treatment, taking from said cohort biological samples containing DNA or protein and testing this for the presence or absence of the ApoE E2 allele; analysing the presence or absence of the ApoE E2 allele as between responders and non- responders; making a comparison with the distribution of the ApoE E2 alleles in a control group of subjects, not suffering from said condition; performing a statistical analysis to determine if there is a statistically significant association between presence or absence of the ApoE E2 allele and response to treatment.
  • the invention thus also provides a method for assessing whether a sub j ect suffering from a condition which may be treated with a neuroleptic agent will be responsive to treatment with a specified neuroleptic agent, said method comprising the steps of: (i) correlating the presence or absence of the ApoE E2 aliele in a population of subjects suffering from a specified condition requiring treament with a neuroleptic agent with observed clinical response to said neuroleptic agent; (ii) testing for the presence or absence of DNA comprising the E2 allele of the ApoE gene or the protein expressed by said gene in a sample containing DNA or protein obtained from said subject, and
  • the invention provides a method for generating a model to assess whether a subject is likely to be responsive to treatment with a neuroleptic agent which method comprises:
  • a cohort of patients diagnosed as suffering from a specified condition eg schizophrenia
  • a neuroleptic agent eg clozapine
  • assessing the outcome of treatment so as to define responders and non-responders according to pre-determined criteria
  • the invention also provides a method for assessing whether a subject suffering from a condition which may be treated with a neuroleptic agent will be responsive to treatment with a specified neuroleptic agent, which comprises comparing said subject's genotype with the model described above.
  • a computer-contolled system may be carried out by a computer-controlled robotic system.
  • a computer-controlled system may also be configured to make the comparison between the subject to be assessed and a pre-determined correlation or model.
  • a computer controlled system may also be configured to give either a positive or negative readout depending on the outcome ofthe comparison. The present invention therefore extends to such computer-controlled or computer-implemented methods.
  • the steps of testing for and detecting the presence or absence of DNA encoding the ApoE E2 allele or the protein expressed by said gene may be carried out either directly or indirectly by any suitable means, such as by techniques well known in the art, and is preferably carried out ex vivo All generally involve the step of collecting a sample of biological material containing DNA or protein from the subject, and then detecting which alleles or protein the subject possesses from that sample.
  • the detecting step may be carried out by collecting a biological sample containing DNA from the subject, and then determining the presence or absence of DNA comprising the E2 allele in the biological sample.
  • Any biological sample which contains the DNA or protein of that subject may be employed, including tissue samples and blood samples, with blood cells being a particularly convenient source.
  • Determining the presence or absence of DNA comprising the E2 allele may be carried out with an oligonucleotide probe labelled with a suitable detectable group; by means of an amplification reaction such as a polymerase chain reaction or ligase chain reaction (the product of which amplification reaction may then be detected with a labelled oligonucleotide probe) or by means of restriction nuclease digestion and electrophoretic separation to detect restriction fragment length polymorphism (RLFP).
  • an amplification reaction such as a polymerase chain reaction or ligase chain reaction (the product of which amplification reaction may then be detected with a labelled oligonucleotide probe) or by means of restriction nuclease digestion and electrophoretic separation to detect restriction fragment length polymorphism (RLFP).
  • amplification reaction such as a polymerase chain reaction or ligase chain reaction (the product of which amplification reaction may then be detected with a labelled oligonucleotide probe) or by
  • the present invention has utility in enabling improvements in the clinical management of patients suffering from schizophrenia.
  • the invention provides direct benefits to the patient in terms of indicating the most appropriate therapy as early as possible in the treatment process and is of wider benefit in terms of health economics.
  • the invention has utility in enabling effective and efficient design of clinical trials with neuroleptic agents.
  • patients who are not likely to respond to either or any of the agents can be excluded.
  • the basis of the present invention namely that patients possessing an E2 allele of the ApoE gene are less likely to respond to clozapine.
  • the present invention provides a method for assessing in a subject the likelihood whether said subject will be non-responsive or responsive to treatment with a drug whose primary mode of action is via a process of altered synaptic activity, the method comprising testing for an detecting the presence or absence of DNA comprising the E2 allele of the ApoE gene, or the protein expressed by said DNA
  • the present invention may also be utilised in screening for drugs whose primary mode of action is via a process of altered synaptic activity, eg antipsychotic, anti- epileptic or antidepressant agents
  • screening may be useful to identify therapeutic agents which may be potentially useful in patients who are not responsive to existing drugs
  • Screening may be effected using in vitro methods or in vivo methods eg utilising transgemc animals, eg mammals such as mice, which express the E2 allehc variant of the ApoE gene
  • transgenic animals may be obtained using procedures which are standard in the field of genetic engineering EXAMPLE

Abstract

On décrit un procédé de détermination chez un sujet de la probabilité selon laquelle celui-ci ne va pas répondre ou va répondre à un traitement effectué à l'aide d'un médicament dont le premier mode d'action s'effectue via un processus d'activité synaptique modifiée. Ce procédé consiste à détecter la présence ou l'absence d'ADN comprenant l'allèle E2 du gène ApoE, ou d'une protéine exprimée par cet ADN, dans un échantillon biologique prélevé sur ledit sujet. A titre d'exemple d'agent neuroleptique atypique, utilisé dans le procédé, on peut citer la clozapine.
PCT/EP1996/005734 1995-12-13 1996-12-11 Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques WO1997021833A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13762/97A AU1376297A (en) 1995-12-13 1996-12-11 Method of predicting a subjects response to neuroleptic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9525481.9 1995-12-13
GBGB9525481.9A GB9525481D0 (en) 1995-12-13 1995-12-13 Novel method

Publications (1)

Publication Number Publication Date
WO1997021833A1 true WO1997021833A1 (fr) 1997-06-19

Family

ID=10785365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005734 WO1997021833A1 (fr) 1995-12-13 1996-12-11 Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques

Country Status (4)

Country Link
AU (1) AU1376297A (fr)
GB (1) GB9525481D0 (fr)
WO (1) WO1997021833A1 (fr)
ZA (1) ZA9610458B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
EP2514840A1 (fr) * 2008-01-02 2012-10-24 Suregene Llc Système de génération d'énergie éolienne et procédé d'installation supplémentaire de générateur d'énergie éolienne dans celui-ci
EP2581455A3 (fr) * 2008-01-17 2013-07-10 Suregene LLC Marqueurs génétiques de maladie mentale
GB2524519A (en) * 2014-03-25 2015-09-30 Pelago Bioscience AB Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025793A1 (fr) * 1994-03-21 1995-09-28 Rhône-Poulenc Rorer S.A. Lapin transgenique sensibilise aux dyslipoproteinemies
WO1995029257A2 (fr) * 1994-04-27 1995-11-02 Mcgill University Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025793A1 (fr) * 1994-03-21 1995-09-28 Rhône-Poulenc Rorer S.A. Lapin transgenique sensibilise aux dyslipoproteinemies
WO1995029257A2 (fr) * 1994-04-27 1995-11-02 Mcgill University Polymorphisme de l'apolipoproteine e et traitement de la maladie d'alzheimer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Dialog Information Service, file 154, Medline, Dialog accession no. 08723289, Medline accession no. 96379828, Harrington CR et al: "Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia", Neurosci Lett (IRELAND) Dec 29 1995, 202 (1-2) p101-4 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
EP2514840A1 (fr) * 2008-01-02 2012-10-24 Suregene Llc Système de génération d'énergie éolienne et procédé d'installation supplémentaire de générateur d'énergie éolienne dans celui-ci
EP2570494A1 (fr) * 2008-01-02 2013-03-20 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570493A1 (fr) * 2008-01-02 2013-03-20 Suregene LLC Marqueurs génétiques de maladie mentale
EP2570495A1 (fr) * 2008-01-02 2013-03-20 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570498A3 (fr) * 2008-01-02 2013-03-27 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570497A3 (fr) * 2008-01-02 2013-03-27 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570496A3 (fr) * 2008-01-02 2013-03-27 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570500A3 (fr) * 2008-01-02 2013-04-03 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570499A3 (fr) * 2008-01-02 2013-04-03 Suregene Llc Marqueurs génétiques de maladie mentale
EP2570501A3 (fr) * 2008-01-02 2013-04-10 Suregene Llc Marqueurs génétiques de maladie mentale
EP2581453A3 (fr) * 2008-01-17 2013-07-10 Suregene Llc Marqueurs génétiques de maladie mentale
EP2581455A3 (fr) * 2008-01-17 2013-07-10 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581454A3 (fr) * 2008-01-17 2013-07-10 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581457A3 (fr) * 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581459A3 (fr) * 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581458A3 (fr) * 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581460A3 (fr) * 2008-01-17 2013-07-17 Suregene LLC Marqueurs génétiques de maladie mentale
EP2581456A3 (fr) * 2008-01-17 2013-07-17 Suregene Llc Marqueurs génétiques de maladie mentale
US9040241B2 (en) 2008-01-17 2015-05-26 Suregene Llc Genetic markers of mental illness
US9738934B2 (en) 2008-01-17 2017-08-22 Clinical Reference Laboratory, Inc. Genetic markers of mental illness
GB2524519A (en) * 2014-03-25 2015-09-30 Pelago Bioscience AB Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
GB2524519B (en) * 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
US11480578B2 (en) 2014-03-25 2022-10-25 Pelago Bioscience AB Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay

Also Published As

Publication number Publication date
ZA9610458B (en) 1998-06-12
GB9525481D0 (en) 1996-02-14
AU1376297A (en) 1997-07-03

Similar Documents

Publication Publication Date Title
Bis et al. Whole exome sequencing study identifies novel rare and common Alzheimer’s-Associated variants involved in immune response and transcriptional regulation
JP5785697B2 (ja) Ｃｎｔｆ遺伝子多型に基づく、精神病および統合失調症の処置方法
KR102622307B1 (ko) 후성유전적 염색체 상호작용
Zimoń et al. Dominant GDAP1 mutations cause predominantly mild CMT phenotypes
Lohoff Overview of the genetics of major depressive disorder
Lappalainen et al. Association between alcoholism and γ‐amino butyric acid α2 receptor subtype in a Russian population
Melville et al. Multiple loci influencing hippocampal degeneration identified by genome scan
Booth et al. Variants in CIB2 cause DFNB48 and not USH1J
JP7281280B2 (ja) トゥレット症候群の診断及び治療方法
Kukshal et al. Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample
Barral et al. Linkage analyses in Caribbean Hispanic families identify novel loci associated with familial late-onset Alzheimer's disease
US20180230541A1 (en) Method for predicting the onset of extrapyramidal symptoms (eps) induced by an antipsychotic-based treatment
US20070065821A1 (en) Methods for the prediction of suicidality during treatment
WO1997021833A1 (fr) Procede de prediction, chez un sujet, de la reponse de celui-ci a des agents neuroleptiques
JP2008505060A (ja) クロザピン処置に対する応答を予測するためのバイオマーカー
US10301678B2 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
WO1996031621A2 (fr) Procede pour determiner la sensibilite de sujets a des agents modulateurs des recepteurs 5-ht¿2?
WO1996017081A1 (fr) Evaluation en vue d'un traitement par des agents neuroleptiques
WO1997032037A1 (fr) Evaluation de la reactivite d'individus a des modulateurs de recepteurs 5-ht2 et, en particulier, du recepteur 5-ht¿2a?
WO2018195184A1 (fr) Procédés de diagnostic et de traitement du tdah chez des sujets positifs à des biomarqueurs
Aldemir et al. Association of 5-HT1A and 5-HT1B Gene Polymorphisms with Obsessive-Compulsive Disorder in a Turkish Population
Zhou et al. Identification of Genomic Rare Variants by Whole Genome Sequencing in Primary Torsion Dystonia
EP1015574A1 (fr) Gene polymorphe contenant des unites de repetition cag et ses utilisations
WO1997034928A1 (fr) Methode d'evaluation des risques de voir se developper des affections psychotiques
KR20070022710A (ko) 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97521755

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase